Loading…
Cohance Lifesciences (COHANCE)₹443.65+0.37%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Cohance Lifesciences reported sales of ₹423 Cr, down 23.2% from Jun 2025, and net profit of −₹45.04 Cr, down 198.0% year on year. For the year to Mar 2026, sales were ₹2,275 Cr and net profit ₹150 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 232 | 220 | 254 | 489 | 606 | 678 | 842 | 551 | 557 | 546 | 621 | 423 |
| Expenses | 133 | 154 | 180 | 363 | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 |
| Operating Profit | 97.61 | 65.76 | 72.74 | 125 | 204 | 236 | 228 | 112 | 121 | 94.66 | 98.69 | 0.99 |
| OPM % | 42.0% | 29.9% | 28.9% | 25.9% | 33.9% | 34.9% | 26.9% | 19.9% | 22.0% | 17.9% | 16.0% | 0.3% |
| Other Income | 19.99 | 13.99 | 17.01 | 18.98 | 15.99 | 21.99 | −4.01 | 5.99 | 16.01 | 0.99 | −18.01 | 11.99 |
| Interest | 0.00 | 2.01 | 2.01 | 10.02 | 10.02 | 11.03 | 10.01 | 10.03 | 9.02 | 9.02 | 9.01 | 7.01 |
| Depreciation | 12.03 | 13.02 | 17.04 | 31.06 | 38.07 | 44.06 | 54.11 | 45.09 | 44.07 | 47.08 | 51.07 | 50.13 |
| Profit before tax | 105 | 64.94 | 70.90 | 103 | 174 | 205 | 161 | 62.96 | 83.94 | 40.94 | 19.99 | −42.95 |
| Tax % | 25.1% | 29.0% | 25.0% | 27.0% | 21.1% | 25.1% | 27.0% | 26.1% | 21.0% | 29.1% | 58.1% | 5.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −10.98 | −5.99 | 0.00 | −2.99 | 1.99 | 0.00 |
| Net Profit | 80.05 | 47.04 | 53.03 | 75.07 | 138 | 153 | 117 | 45.98 | 66.06 | 28.99 | 8.01 | −45.04 |
| EPS (Rs) | 3.12 | 1.83 | 2.11 | 2.97 | 5.45 | 6.00 | 4.72 | 1.27 | 1.95 | 0.95 | 0.50 | −0.62 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 379 | 836 | 1,012 | 1,324 | 1,344 | 1,054 | 1,201 | 2,275 | 2,147 |
| Expenses | 206 | 449 | 567 | 737 | 766 | 645 | 821 | 1,841 | 1,824 |
| Operating Profit | 171 | 384 | 441 | 580 | 572 | 405 | 374 | 426 | 315 |
| OPM % | 44.9% | 46.0% | 43.9% | 44.0% | 43.0% | 38.9% | 30.9% | 19.0% | 14.7% |
| Other Income | 0.99 | 66.01 | 67.99 | 133 | 45.96 | 62.01 | 58.04 | 5.01 | 10.98 |
| Interest | 3.01 | 23.03 | 12.03 | 9.02 | 13.03 | 7.01 | 12.01 | 37.04 | 34.06 |
| Depreciation | 12.02 | 24.03 | 32.06 | 39.08 | 48.07 | 55.12 | 77.16 | 187 | 192 |
| Profit before tax | 158 | 405 | 467 | 668 | 559 | 405 | 344 | 207 | 102 |
| Tax % | 31.0% | 22.0% | 23.1% | 32.1% | 27.0% | 26.0% | 23.0% | 27.1% | — |
| Exceptional items | 0.00 | 4.99 | 2.99 | 49.94 | 10.99 | 32.97 | 30.94 | −17.99 | −1.00 |
| Net Profit | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 150 | 58.02 |
| EPS (Rs) | — | 12.44 | 14.22 | 17.82 | 16.15 | 11.81 | 10.51 | 4.67 | 2.78 |
| Dividend payout % | 0.0% | 19.9% | 13.9% | 27.9% | 36.9% | 0.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 13.04 | 25.06 | 25.07 | 25.06 | 25.06 | 25.06 | 38.09 |
| Reserves | 579 | 832 | 1,155 | 1,502 | 1,710 | 2,026 | 1,668 | 3,873 |
| Borrowings | 83.17 | 186 | 143 | 97.03 | 70.05 | 65.04 | 279 | 400 |
| Other Liabilities | 124 | 143 | 152 | 206 | 161 | 139 | 1,061 | 1,425 |
| Total Liabilities | 785 | 1,174 | 1,475 | 1,832 | 1,967 | 2,256 | 3,033 | 5,737 |
| Fixed Assets | 271 | 357 | 442 | 535 | 663 | 671 | 1,713 | 3,376 |
| CWIP | 111 | 102 | 96.11 | 30.06 | 165 | 179 | 256 | 173 |
| Investments | 6.99 | 338 | 541 | 598 | 535 | 904 | 337 | 528 |
| Other Assets | 395 | 377 | 396 | 668 | 602 | 503 | 727 | 1,659 |
| Inventories | 157 | 176 | 201 | 284 | 314 | 232 | 167 | 563 |
| Trade receivables | 148 | 117 | 102 | 236 | 111 | 134 | 284 | 681 |
| Cash & equivalents | 12.98 | 13.96 | 9.97 | 46.90 | 67.90 | 49.89 | 88.86 | 59.90 |
| Total Assets | 785 | 1,174 | 1,475 | 1,832 | 1,967 | 2,256 | 3,033 | 5,737 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 49.97 | 406 | 382 | 330 | 457 | 357 | 288 | 368 |
| Cash from investing activity | −64.87 | −412 | −310 | −136 | −194 | −361 | −252 | −255 |
| Cash from financing activity | 25.96 | 6.98 | −75.84 | −156 | −242 | −13.98 | 2.99 | −165 |
| Net cash flow | 10.99 | 0.99 | −4.99 | 36.94 | 19.98 | −17.98 | 37.98 | −50.91 |
| Capex | 56.80 | 103 | 111 | 74.74 | 285 | 51.85 | 155 | 219 |
| Free cash flow | −5.99 | 303 | 271 | 255 | 171 | 306 | 132 | 169 |
| CFO / OP % | 49.0% | 128.1% | 111.1% | 88.1% | 105.0% | 115.1% | 99.1% | 102.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 141 | 50 | 36 | 64 | 29 | 45 | 86 | 109 |
| Inventory days | 557 | 279 | 244 | 260 | 280 | 269 | 200 | 311 |
| Days payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 | 157 |
| Cash conversion cycle | 510 | 218 | 181 | 229 | 248 | 266 | 191 | 264 |
| Working capital days | 204 | 63 | 55 | 107 | 98 | 114 | 73 | 174 |
| ROCE % | — | 50.1% | 40.1% | 41.1% | 32.1% | 19.0% | 15.1% | 8.1% |
For the Jun 2026 quarter, Cohance Lifesciences reported sales of ₹423 Cr, down 23.2% year on year and net profit of −₹45.04 Cr, down 198.0% year on year. The operating margin was 0.3%.
Cohance Lifesciences' sales for the year to Mar 2026 were ₹2,275 Cr; over the last twelve months they were ₹2,147 Cr.
Net profit for the year to Mar 2026 was ₹150 Cr, and ₹58.02 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.78.
Cohance Lifesciences reported borrowings of ₹400 Cr at Mar 2026, against cash and equivalents of ₹59.90 Cr.
Cash from operations was ₹368 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹169 Cr.